Kangmei Pharmaceutical Co., Ltd. (SHA:600518)

Market Cap	17.98B -35.6%
Revenue (ttm)	4.97B -6.2%
Net Income	29.46M +203.3%
EPS	0.00 +266.5%
Shares Out	13.83B
PE Ratio	605.51
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	56,964,463
Open	1.290
Previous Close	1.290
Day's Range	1.290 - 1.310
52-Week Range	1.160 - 2.160
Beta	0.58
Analysts	n/a
Price Target	n/a
Earnings Date	Oct 31, 2026

About Kangmei Pharmaceutical

Kangmei Pharmaceutical Co., Ltd. produces and sells Chinese herbal medicines in China. The company offers Chinese patent medicines, chemical medicines, and health food products. It also engages in the operation of Chinese medicinal materials markets; production and sale of medical devices; and operation of pharmaceutical logistics system. The company provides its products through medical institution resources, smart pharmacies, OTC retail, chain drug stores, direct sales, medical e-commerce, mobile medical care, etc. Kangmei Pharmaceutical Co.,...

• Industry: Drug Manufacturers - Specialty & Generic
• Sector: Healthcare
• Founded: 1997
• Employees: 5,492
• Stock Exchange: Shanghai Stock Exchange
• Ticker Symbol: 600518

Financial Performance

In 2025, Kangmei Pharmaceutical's revenue was 5.25 billion, an increase of 1.22% compared to the previous year's 5.19 billion. Earnings were 10.33 million, an increase of 20.46%.

Data Sources: S&P Global Market Intelligence and Financial Modeling Prep

Fundamental and historical data is provided by S&P Global Market Intelligence. Delayed stock pricing data is provided by Financial Modeling Prep.

Last checked:

Oct 21, 2026

Data Sources Report a data error